| Mylan gets US FDA final approval for generic Doryx tablets |
pharmabiz.comDoxycycline hyclate DR tablets had US sales of approximately $264.1 million for the 12 months ending December 31, 2011, according to IMS Health. Currently, Mylan has 173 ANDAs pending FDA approval representing $98.3 billion in annual sales, ...
|
| SwedishAmerican named one of most integrated in U.S. |
Rockford Register StarBy Anonymous SwedishAmerican Health System was named one of the nation's 100 most integrated health care networks by IMS Health, a consulting firm that analyzes the progress of local and regional non-specialty integrated health care networks.
|
| Mylan Receives Final FDA Approval for First Generic Version of Doryx Tablets ... |
Benzinga31, 2011, according to IMS Health. Currently, Mylan has 173 ANDAs pending FDA approval representing $98.3 billion in annual sales, according to IMS Health. Forty-three of these pending ANDAs are potential first-to-file opportunities, representing $26.6 ...
|
| Mylan Receives Final FDA Approval for First Generic Version of Doryx® Tablets ... |
Sacramento Bee31, 2011, according to IMS Health. Currently, Mylan has 173 ANDAs pending FDA approval representing $98.3 billion in annual sales, according to IMS Health. Forty-three of these pending ANDAs are potential first-to-file opportunities, representing $26.6 ...
|
| Mylan Receives Final FDA Approval for First Generic Version of Doryx Tablets ... |
Citybizlist (press release)31, 2011, according to IMS Health. Currently, Mylan has 173 ANDAs pending FDA approval representing $98.3 billion in annual sales, according to IMS Health. Forty-three of these pending ANDAs are potential first-to-file opportunities, representing $26.6 ...
|
| Mylan Receives Final FDA Approval for First Generic Version of Doryx® Tablets ... |
MarketWatch (press release)31, 2011, according to IMS Health. Currently, Mylan has 173 ANDAs pending FDA approval representing $98.3 billion in annual sales, according to IMS Health. Forty-three of these pending ANDAs are potential first-to-file opportunities, representing $26.6 ...
|
| Alchemia-Update On Fondaparinux Sales |
PT NewsThe latest weekly data from US IMS Health shows that Dr Reddy's generic fondaparinux reported prescription market share of 18%. This represents recent sales in excess of $1.4m per week. The retail segment of the market (non-hospital) is known to be ...
|
